Swan Capital’s Coherus Oncology CHRS Stock Holding History

Swan Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,300	Closed	-$2.2K	–	587
2026 Q1	$2.2K	Hold	1,300	–	–	﹤0.01%	351
2025 Q4	$1.85K	Hold	1,300	–	–	﹤0.01%	338
2025 Q3	$2.13K	Hold	1,300	–	–	﹤0.01%	306
2025 Q2	$951	Hold	1,300	–	–	﹤0.01%	383
2025 Q1	$1.05K	Hold	1,300	–	–	﹤0.01%	282
2024 Q4	$1.79K	Hold	1,300	–	–	﹤0.01%	238
2024 Q3	$1.35K	Hold	1,300	–	–	﹤0.01%	246
2024 Q2	$2.25K	Buy	+1,300	New	+$2.62K	﹤0.01%	194

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Swan Capital's CHRS Position: Q2 2026 in Review

Swan Capital sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 1,300 shares — an estimated $2.2K sold.

Swan Capital first reported a position in CHRS in Q2 2024 and held it in 8 quarters. The position peaked at $2.25K in Q2 2024. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

Swan Capital reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
Swan Capital sold 1,300 Coherus Oncology shares in Q2 2026, an estimated $2.2K.
Swan Capital first reported a position in Coherus Oncology in Q2 2024 and held it in 8 quarters.
Swan Capital's Coherus Oncology position peaked at $2.25K in Q2 2024.
146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Swan Capital's 13F filing for Q2 2026, filed 13 Aug 2026.